Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors
AssigneeNovatis AG
InventorsGermo Hans Gericke, Herbert Anton Schmid, Mario Roberto Maldonado Lutomirsky, Li Li
Life of this patent
Estimating the term…
Abstract
The present invention relates to a combination which comprises (a) a somatostatin analogue and (b) a 11beta-hydroxylase inhibitor; each in free form or in the form of a pharmaceutical acceptable salt thereof; the use of such a combination for the preparation of a medicament for the treatment of diseases associated with increased stress hormone levels; a commercial package or product comprising such a combination; and to a method of treatment of a warm-blooded animal, especially a human.
Claims13
A combination of (a) Compound A (R)-4-(6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile:
- and (b) a somatostatin analogue, wherein (a) and (b) are present in each case in free form, complex form or in the form of a pharmaceutically acceptable salt.
Compound A (R)-4-(6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile for use in combination of a somatostatin analogue for treating Cushing's syndrome, preferably said Cushing's syndrome is Cushing's disease.
A method of treating Cushing's syndrome, preferably said Cushing's syndrome is Cushing's disease, comprising administering (1) Compound A (R)-4-(6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile and (2) a somatostatin analogue to a patient simultaneously, separately or sequentially.
12-13. (canceled)
Dependencies are inferred from the claim text.